Telmisartan versus EnalapRil In heart failure with redUced ejection fraction patients with Moderately impaired kidney Functions; randomized controlled trial: “TRIUMF trial”

The Egyptian Heart Journal

Table 3 Data by the 6-months assessment

	Telmisartan	Enalapril	P-value
RAASi standardized dose*	100% [100–100]	100% [25–100]	< 0.001
Achieving ≥ 50% of the target RAASi dose	95.6%	72.9%	0.009
Occurrence of DR	23.8%	39.1%	0.094
Composite of any DR-DC	35.7%	56.5%	0.041
Peak serum creatinine	1.70 ± 0.51	1.72 ± 0.69	0.853
Estimated GFR	48.6 ± 10.7	53.9 ± 17.7	0.098
Serum K	4.65 ± 0.59	5.57 ± 0.60	0.558
Rate of WRF (1)	19.5%	25%	0.365
Rate of WRF (2)	9.8%	11.4%	0.546
Rate of WRF (3)	7.3%	13.6%	0.278
Maintaining MRA therapy	93%	84%	0.198
Maintaining BB therapy	93%	86%	0.278
BB standardized dose*	47.9 ± 33.8%	50 ± 37.5%,	0.783
Loop diuretic standardized dose^†	120 ± 123	176 ± 208	0.143
New composite of all-cause death or HFH	18.2%	34%	0.069
New all cause death	3 (6.8%)	3 (6.4%)	0.63
New HFH	15.9%	25.5%	0.192
NYHA class shifts between baseline-to-6-months	− 1 [− 2, 0]	0 [− 1, 1]	0.017

Bold refers to statistically significant p value
BB—Beta adrenergic blocker; DC—discontinuation; DR—dose reduction; GFR—glomerular filtration rate; HFH—heart failure re-hospitalization; MRA—Mineralocorticoid antagonists; NYHA—New York Heart Association class; RAASi—Renin–angiotensin–aldosterone system inhibitors; WRF—worsening renal function defined as absolute rise in the serum creatinine by 0.3 mg/dl, or by 0.5 mg/dl or as relative decline of the eGFR by ≥ 20% compared to prior assessments in (1), (2) and (3), respectively
^*Representing percentage from target dose; † Expressed in mean ± standard deviation (SD) of Frusemide equivalents, considering 20 mg of Torsemide, 1 mg of Bumetanide and 40 mg of Frusemide as equivalents